30 results
8-K
EX-99.1
PRAX
Praxis Precision Medicines Inc
9 Aug 23
Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2023 Financial Results
8:27am
for ulixacaltamide in Q4 2023 after favorable End-of-Phase 2 meeting with FDA
PRAX-628 Phase 1 study showed consistent safety profile and target engagement
S-1/A
EX-10.1
o9oice5minwf
9 Oct 20
IPO registration (amended)
6:09am
S-1
EX-10.1
udsv3v q1p3esqfa
25 Sep 20
IPO registration
5:19pm
S-1
EX-10.2
5jme3c8vl2rfep jd
25 Sep 20
IPO registration
5:19pm
10-Q
2g8mfvd2o69rh9abpl
23 Nov 20
Quarterly report
4:16pm
DRS
EX-10.3
1c9 zb72xsg
22 Jul 20
Draft registration statement
12:00am
S-1
EX-10.3
jx5rxakg10fgalnncez
25 Sep 20
IPO registration
5:19pm
S-1
x7oxu
25 Sep 20
IPO registration
5:19pm
S-1/A
lcc08 asl
9 Oct 20
IPO registration (amended)
6:09am
424B4
1ysb40ejd7xit7qrm
16 Oct 20
Prospectus supplement with pricing info
4:02pm